Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-dose study of etranacogene dezaparvovec in adolescent males with severe or moderately severe hemophilia B
MOH_2025-10-27_015412Phase 3Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Oct 2025
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on MOH_2025-10-27_015412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-27_015412.